Overview
AUPH market data
Price History
AUPH price chart · 1M
- O
- 16.55
- H
- 16.77
- L
- 16.31
- C
- 16.44
- Vol
- 40,290.00
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $16.55
- Previous Close
- $16.60
- Day High
- $16.77
- Day Low
- $16.31
- 52 Week High
- $19.25
- 52 Week Low
- $14.37
- 7 Day Return
- -2.67%
- 30 Day Return
- -0.60%
- 90 Day Return
- -2.11%
- 1 Year Return
- +7.35%
- Daily Notional Volume
- $662.2K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- 6.99 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $2.07 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.42 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 100.8% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $10.34 – $19.25 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $2.2B · P/B 3.62 · P/S 7.05.
Company News
8 captured
Lupus Nephritis Market on a Growth Trajectory at a CAGR of 7% During the Forecast Period (2026–2036), as Innovative Therapies Gain Momentum | DelveInsightGlobenewswire Inc ·
RBC Capital Maintains Sector Perform on Aurinia Pharmaceuticals, Raises Price Target to $16Benzinga ·